Western Blot: ERManI Antibody (3C2) [NBP2-13167] - Western blot analysis of ERManI expression in 1) NTERA-2 and 2) A-431 whole cell lysates.
Immunocytochemistry/ Immunofluorescence: ERManI Antibody (3C2) [NBP2-13167] - ERManI antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight ...read more
Immunohistochemistry: ERManI Antibody (3C2) [NBP2-13167] - IHC staining of ERManI in human breast cancer using DAB with hematoxylin counterstain.
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Tris-glycine, 150mM NaCl pH 7.5
0.05% Sodium Azide
Protein G purified
This ERManI Antibody (3C2) is useful for Immunocytochemistry/Immunofluorescence, Western Blot, ELISA, Immunoprecipitation and Immunohistochemistry on paraffin embedded sections. In ICC/IF, endoplasmic reticulum membrane staining was observed in HeLa cells. In Western Blot, a band is seen ~90 kDa representing ERManI. In IHC-P, staining was observed in the endoplasmic reticulum of human breast cancer tissue. Prior to immunostaining paraffin tissues, antigen retrieval with sodium citrate buffer (pH 6.0) is recommended.
Read Publications using NBP2-13167 in the following applications:
ERManI, also known as endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase or MAN1B1, is a putative ER resident mannosidase that plays a rate-limiting role in generating a signal that targets misfolded N-linked glycoproteins for ER-associated degradation (ERAD). ERManI codes for an enzyme that converts Man9GlcNAc to Man8GlcNAc isomer B during N-glycan biosynthesis. It also facilitates the trimming of Man5-6GlcNAc2 in the endoplasmic reticulum associated degradation pathway. Multiple transcript variants of ERManI can result from alternative splicing, and a related pseudogene can be found on chromosome 11. Research has found that mutations on the ERManI gene can result in autosomal-recessive intellectual disabilities and developmental delays (PMID: 21763484). ERManI is predominately localized to the Golgi and endoplasmic reticulum.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.